Group 1: Capital Increase Announcement - The company approved a capital increase of 466 million yuan for five wholly-owned subsidiaries to support operational development [1] - The subsidiaries involved are Yunnan Jianzhijia Medical Service Co., Yunnan Jianzhijia Chongqing Qinkang Pharmaceutical Co., Liaoning Jianzhijia Pharmaceutical Co., Hebei Tangren Pharmaceutical Co., and Hebei Jianzhijia Tangren Chain Pharmacy Co. [1] - The capital increase will be completed within one year after the board's approval [1] Group 2: Guarantee for Subsidiary - The company provided a guarantee of 20 million yuan for its wholly-owned subsidiary, Yunnan Jianzhijia Chain Health Pharmacy Co. [4] - As of the announcement date, the total guarantees provided by the company for the subsidiary amounted to 531.57 million yuan [4] - The company has no overdue external guarantees, and all guarantees are for wholly-owned subsidiaries [4][10] Group 3: Guarantee Details - The company signed a maximum guarantee contract with Fudian Bank for a credit limit of 20 million yuan for the subsidiary [5] - The total credit limit for the company and its subsidiaries is capped at 8 billion yuan, with specific allocations for operational and project financing [6][7] - The guarantees are intended to support the subsidiary's operational development and improve overall financing efficiency [9]

证券代码：605266 证券简称：健之佳 公告编号：2025-036 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次被担保方云南健之佳连锁健康药房有限公司（以下简称"连锁药房"） 为健之佳医药连锁集团股份有限公司（以下简称"公司"）100%持股的全资子公 司。 本次公司为连锁药房担保金额 2,000 万元，截至本公告披露日，公司为 连锁药房已实际提供的担保余额为 53,156.52 万元。 本次担保额度在股东会已决策授权担保的范围内。详见公司在上海证券交易 所网站（www.sse.com.cn）及指定信息披露媒体上于 2025 年 4 月 29 日披露的《关 于公司及子公司向金融机构申请综合授信额度及为综合授信额度提供担保的公 告》及于 2025 年 5 月 22 日披露的《2024 年年度股东会决议公告》。 截至公告披露日，公司对外担保均系为全资子公司提供的担保，不涉及 集团外担保，公司无逾期对外担保。 风险提示：截至本公告披露日，公司为全 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-035 健之佳医药连锁集团股份有限公司 新增注册资本将按董事会决议的时限缴足。 1 特此公告。 健之佳医药连锁集团股份有限公司董事会 关于公司对五家全资子公司增资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健之佳医药连锁集团股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第六届董事会第十次会议，审议通过《关于公司对五家全资子公司进行增 资的议案》。 公司根据经营发展需要，依据《公司法》、《公司章程》的相关规定，以自有 资金对云南健之佳医疗服务有限公司、云南健之佳重庆勤康药业有限公司、辽宁 健之佳医药有限公司、河北唐人医药有限责任公司、河北健之佳唐人连锁药房有 限公司 5 家全资子公司进行增资。合计增资金额 46,600 万元，拟在董事会审议 通过后一年内分一次或分次缴足。具体内容详见公司于 2025 年 4 月 29 日披露的 《关于公司对五家全资子公司进行增资的公告》 截至本公告日，5家全资子公司已办妥注册资本变更登记手续并换 ...

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...

Core Viewpoint - The legal opinion from Beijing DeHeng Law Offices confirms that the differentiated dividend distribution plan of Jianzhijia Pharmaceutical Chain Group Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6]. Group 1: Reasons for Differentiated Dividend - Jianzhijia held its sixth board meeting on June 20, 2024, approving a share repurchase plan using self-owned funds to maintain company value and shareholder rights, with 1,143,260 shares repurchased by the announcement date [2]. - A subsequent board meeting on September 19, 2024, approved another share repurchase plan, resulting in an additional 903,400 shares repurchased [4]. - On October 29, 2024, a third board meeting approved a plan to repurchase 4,338,200 shares, totaling 6,384,860 shares that will not participate in profit distribution [4]. Group 2: Differentiated Dividend Plan - The company plans to distribute a cash dividend of RMB 11.00 per 10 shares (including tax) based on the total share capital minus the repurchased shares, resulting in a total of 162,973,874.80 RMB to be distributed [5]. - The total share capital as of the legal opinion date is 154,542,928 shares, with 6,384,860 shares excluded from the distribution, leading to 148,158,068 shares participating in the dividend [5]. Group 3: Calculation Basis for Differentiated Dividend - The reference price for ex-dividend is calculated as approximately 22.0500 RMB per share, based on the closing price of 23.15 RMB minus the cash dividend [5]. - The virtual distribution calculation shows a minor impact on the ex-dividend reference price, estimated at approximately 0.2059% [5]. Group 4: Conclusion - The legal opinion concludes that the differentiated dividend distribution plan is in accordance with the Company Law, Securities Law, and relevant regulations, ensuring no detriment to the company or its shareholders [6].

Core Points - The company announced a cash dividend of 1.10 RMB per share for A shares [1][3] - The total cash dividend to be distributed amounts to approximately 162.97 million RMB, based on the total shares eligible for distribution [3][4] Dividend Distribution Details - The record date for the dividend is set for June 17, 2025, with the last trading day and ex-dividend date both on June 18, 2025 [3][5] - The total share capital of the company is 154,542,928 shares, with 6,384,860 shares in the repurchase account, resulting in 148,158,068 shares eligible for the dividend [3][4] - The cash dividend distribution will not include shares held in the repurchase account [5] Tax Implications - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 1.10 RMB per share [7] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the sale of the shares [7][8] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 0.99 RMB per share [8]

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 差异化分红事项的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650032 北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司差异化分红事项的法律意见 北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 差异化分红事项的 法律意见 致：健之佳医药连锁集团股份有限公司 本所接受健之佳医药连锁集团股份有限公司（以下简称"公司"或"健之 佳"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 7 号—回购股份》（以下简称"《回购 指引》"）等法律、法规、规范性文件以及《健之佳医药连锁集团股份有限公司章 程》（以下简称"《公司章程》"）的规定，按照律师行业公认的业务标准、道德规 范和勤勉尽责精神，出具本法律意 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-034 健之佳医药连锁集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利1.10元 2024年度可供股东分配的未分配利润为722,051,604.31元。拟以2024年度利 润分配时股权登记日的总股本扣除股份回购证券账户专户已回购股份后的股份数 为基数，每10股派发现金红利人民币11.00元（含税）。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/17 | － | 2025/6/18 | 2025/6/18 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经健之佳医药连锁集团股份有限公司（以下简称"公司"） 2025 年 5 月 21 日的2024年年度股东大会审议通过。 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [1][7]. Core Views - The company's performance in 2024 was impacted by an increase in sales expense ratio, leading to a decline in net profit [4]. - The company achieved a total revenue of 9.283 billion yuan in 2024, representing a year-over-year growth of 2.23%, while the net profit decreased by 69.08% to 128 million yuan [4][10]. - The company continues to expand its store count, reaching a total of 5,486 stores by the end of 2024, with a net increase of 370 stores [5]. - The company has over 26 million effective members, with member consumption accounting for nearly 70% of total sales, supporting stable growth [5]. - The company is focusing on differentiated competition and multi-channel operations, with online channel revenue growing by 19.51% year-over-year, accounting for 27.9% of total revenue [6]. Financial Summary - The company forecasts revenues of 10.1 billion yuan, 11.05 billion yuan, and 12.003 billion yuan for 2025, 2026, and 2027, respectively, with year-over-year growth rates of 8.80%, 9.41%, and 8.62% [7][10]. - The projected net profits for the same years are 196 million yuan, 242 million yuan, and 271 million yuan, with growth rates of 53.1%, 23.3%, and 12.2% [7][10]. - The company’s earnings per share (EPS) are expected to be 1.27 yuan, 1.56 yuan, and 1.76 yuan for 2025, 2026, and 2027, respectively [10].

Investment Rating - The report maintains a "Buy" investment rating for the company [1][7]. Core Views - The company's performance in 2024 was impacted by an increase in sales expense ratio, leading to a decline in net profit [4]. - The company achieved a revenue of 9.283 billion yuan in 2024, representing a year-on-year growth of 2.23%, while the net profit decreased by 69.08% to 128 million yuan [4][10]. - The company continues to expand its store count, reaching a total of 5,486 stores by the end of 2024, with effective membership exceeding 26 million [5][6]. Financial Performance - The company’s revenue and profit forecasts for 2025-2027 are as follows: - Revenue: 10.1 billion yuan (2025), 11.05 billion yuan (2026), 12.003 billion yuan (2027) with respective growth rates of 8.80%, 9.41%, and 8.62% [7][10]. - Net profit: 196 million yuan (2025), 242 million yuan (2026), 271 million yuan (2027) with growth rates of 53.1%, 23.3%, and 12.2% [7][10]. - The company’s gross margin for 2024 was 34.78%, a decrease of 1.10 percentage points year-on-year [4]. Market Position and Strategy - The company has a compound annual growth rate of 27.32% in the number of direct-operated pharmacies from 2019 to 2024 [6]. - The company is focusing on differentiated competition and multi-channel operations, with online channel revenue growing by 19.51% in 2024, accounting for 27.9% of total revenue [6]. - The company is actively expanding in regions such as Yunnan, Hebei, Chongqing, and Liaoning, aiming to catch up with leading pharmacy chains [6].